Your history, goals, side effects, and lab results can all shape the plan
The drug was first patented in 2016, and after successful trials, Eli Lilly applied for FDA approval in October 2021
Add a handful of spinach for a fiber boost
Your clinician works with you to find the right fit for your budget, health needs, and long-term goals
Peptide sequence: H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 Mechanism of action: Exendin-4 is a GLP-1R agonist that binds with the GLP-1 receptor, which exerts similar antidiabetic effects as observed in the case of DPP-IV inhibitors sitagliptin and vildagliptin (as mentioned above)
The best dose is the one that produces acceptable results with manageable side effects